| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
The viability of U87 and U251 astrocytoma cells is dose-dependently inhibited by hematoporphyrin dihydrochloride (20-120 nM; 60 minutes), with IC50 values of 85 and 166 nM, respectively [2]. Hematoporphyrin (85 nM; 60 min) causes U87 cells to contract and fragment when exposed to red light, changing the morphology of the cells [2].
|
|---|---|
| ln Vivo |
Under red light illumination, hematoporphyrins (5–10 mg/kg; intraperitoneally injected for 2 months) can quickly enlarge tumors because of the immediate impact of photoactivated porphyrins on tumor cells and the subsequent impacts on blood vessels. Second-hand
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: U87 and U251 Cell Tested Concentrations: 20, 40, 60, 80, 100, 120 nM Incubation Duration: 60 minutes Experimental Results: Inhibited cell viability in a dose-dependent manner. More effective under red light than white light. Apoptosis analysis [2] Cell Types: U87 Cell Tested Concentrations: 85 nM Incubation Duration: 60 minutes Experimental Results: Apoptotic nuclei were induced in U87 cells at low cell density. Induces ROS and reduces mitochondrial membrane potential. |
| Animal Protocol |
Animal/Disease Models: Wistar albino rats of both sexes (20d; 60-80g) with subcutaneoussolid Yoshida liver cancer AH-130 [3]
Doses: 5, 10mg/kg Route of Administration: daily intraperitoneal (ip) injection for the first 10 days, then Biweekly results for 2 months: No tumors were palpable after the rats were exposed to light for several days. The skin heals completely and the hair grows back. Large areas of coagulative necrosis appeared in the tumor 24 hrs (hrs (hours)) after phototherapy (×40). |
| References |
|
| Molecular Formula |
C34H40CL2N4O6
|
|---|---|
| Molecular Weight |
671.6106
|
| Exact Mass |
670.232
|
| CAS # |
17696-69-4
|
| Related CAS # |
Hematoporphyrin;14459-29-1
|
| PubChem CID |
159830
|
| Appearance |
Solid powder
|
| Boiling Point |
1192.7ºC at 760 mmHg
|
| Flash Point |
675.1ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| LogP |
4.249
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
46
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
WZQQOXSHARXAID-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C34H38N4O6.2ClH/c1-15-21(7-9-31(41)42)27-14-28-22(8-10-32(43)44)16(2)24(36-28)12-29-34(20(6)40)18(4)26(38-29)13-30-33(19(5)39)17(3)25(37-30)11-23(15)35-27;;/h11-14,19-20,37-40H,7-10H2,1-6H3,(H,41,42)(H,43,44);2*1H
|
| Chemical Name |
3-[18-(2-carboxyethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid;dihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product is not stable in solution, please use freshly prepared working solution for optimal results. (2). Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~93.06 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4890 mL | 7.4448 mL | 14.8896 mL | |
| 5 mM | 0.2978 mL | 1.4890 mL | 2.9779 mL | |
| 10 mM | 0.1489 mL | 0.7445 mL | 1.4890 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
